$Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas$

Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas

Alliance A021501 is the first randomized trial to evaluate stereotactic body radiation therapy (SBRT) for borderline resectable pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant chemotherapy. In this post hoc study, we reviewed the quality of radiation therapy (RT) delivered. SBRT (6.6 Gy ×...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of radiation oncology, biology, physics biology, physics, 2024-09, Vol.120 (1), p.111-119
Hauptverfasser:	Tchelebi, Leila T., Segovia, Diana, Smith, Koren, Shi, Qian, Fitzgerald, T.J., Chuong, Michael D., Zemla, Tyler J., O'Reilly, Eileen M., Meyerhardt, Jeffrey A, Koay, Eugene J., Lowenstein, Jessica, Shergill, Ardaman, Katz, Matthew H.G., Herman, Joseph M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - pathology Adenocarcinoma - radiotherapy Adenocarcinoma - surgery Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Pancreatic Ductal - pathology Carcinoma, Pancreatic Ductal - radiotherapy Carcinoma, Pancreatic Ductal - surgery Female Fluorouracil - administration & dosage Fluorouracil - therapeutic use Humans Irinotecan Leucovorin - administration & dosage Leucovorin - therapeutic use Male Neoadjuvant Therapy Oxaliplatin - administration & dosage Oxaliplatin - therapeutic use Pancreatic Neoplasms - pathology Pancreatic Neoplasms - radiotherapy Quality Assurance, Health Care Radiation Dose Hypofractionation Radiosurgery Radiotherapy Planning, Computer-Assisted
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!